The principal Phase II goal of the COBRE Center for Targeted Therapeutics (CTT) is to conduct vital research oriented at identifying novel drug targets and discovering new targeted drugs, while enhancing the career development and research competitiveness of Center investigators. Targeted therapeutics is a broad term for research that seeks to develop new and more effective classes of drugs against various diseases, by selectively aiming these drugs at molecular and cellular targets that play a key role in the disease. The area of Targeted Therapeutics has been chosen because of its societal impact, the emergence of common technologies driving therapeutics research in different disease areas, and the presence of a critical core of senior faculty with broad acumen and trans-disciplinary vision in Targeted Therapeutics at USC. During Phase I, junior investigators leading CTT research projects (target PIs) were awarded five R01s and several smaller grants, and pilot project recipients received two R01s and several other grants, for a total of close to $14 million. Four target PIs received promotion and tenure and almost 50 published papers acknowledged COBRE support. Three resource cores established by the CTT provided services to 64 different laboratories and organized training workshops and a new graduate course. To build upon the success of Phase I, we will pursue the following Specific Aims.
Aim 1. Support high-impact research projects and assist junior scientists in Targeted Therapeutics in their professional development and competitiveness for NIH grants, in a collaborative and nurturing environment. Target junior faculty members include four highly promising scientists, each of whom will be mentored by two senior scientists with different areas of expertise relevant to their research.
Aim 2. Establish sustainable research infrastructure through the further development of strategic Cores for Targeted Therapeutics research. The Center supports research cores in Functional Genomics, Drug Design and Synthesis, and Microscopy and Flow Cytometry. These cores will provide both specialized services and intellectual scientific support.
Aim 3. Assure long-term development of the CTT by broadening collaborative networking, fostering continuous recruitment, supporting new faculty in Targeted Therapeutics, and supporting pilot research projects, with an emphasis on drug discovery and preparation for multi-investigator and SBIR/STTR grant applications. CTT will conduct regular meetings and seminars and promote external collaborations. CTT will participate in the recruitment of five new junior faculty members to USC and will continue working with the ?graduated? target faculty, assuring that they continue to make important discoveries and win grants. Continued success of the CTT will make an impact on the public health, scientific education and economic development of the State.

Public Health Relevance

The Center for Targeted Therapeutics (CTT) brings together junior and senior faculty with a common interest in the discovery of new molecular targets and prototype drugs for the treatment of common and serious diseases. Within the CTT junior faculty are mentored by established investigators who are experts in their respective fields. CTT faculty members work together to promote the rapid advancement of their field, and to train the next generations of scientists and mentors.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
2P20GM109091-06
Application #
9794379
Study Section
Special Emphasis Panel (ZGM1)
Program Officer
Gao, Hongwei
Project Start
2014-07-10
Project End
2024-04-30
Budget Start
2019-08-01
Budget End
2020-04-30
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of South Carolina at Columbia
Department
Type
Schools of Pharmacy
DUNS #
041387846
City
Columbia
State
SC
Country
United States
Zip Code
29208
Liang, Jiaxin; Chen, Mengqian; Hughes, Daniel et al. (2018) CDK8 Selectively Promotes the Growth of Colon Cancer Metastases in the Liver by Regulating Gene Expression of TIMP3 and Matrix Metalloproteinases. Cancer Res 78:6594-6606
Chukwurah, Evelyn; Patel, Rekha C (2018) Stress-induced TRBP phosphorylation enhances its interaction with PKR to regulate cellular survival. Sci Rep 8:1020
Singh, Priyanka; Jenkins, Laura M; Horst, Ben et al. (2018) Inhibin Is a Novel Paracrine Factor for Tumor Angiogenesis and Metastasis. Cancer Res 78:2978-2989
Wyatt, Michael D; Reilly, Nicole M; Patel, Shikha et al. (2018) Thiopurine-induced mitotic catastrophe in Rad51d-deficient mammalian cells. Environ Mol Mutagen 59:38-48
Serrao, Anne; Jenkins, Laura M; Chumanevich, Alexander A et al. (2018) Mediator kinase CDK8/CDK19 drives YAP1-dependent BMP4-induced EMT in cancer. Oncogene 37:4792-4808
Varadaraj, Archana; Magdaleno, Carina; Mythreye, Karthikeyan (2018) Deoxycholate Fractionation of Fibronectin (FN) and Biotinylation Assay to Measure Recycled FN Fibrils in Epithelial Cells. Bio Protoc 8:
Liu, Changlong; Banister, Carolyn E; Weige, Charles C et al. (2018) PRDM1 silences stem cell-related genes and inhibits proliferation of human colon tumor organoids. Proc Natl Acad Sci U S A 115:E5066-E5075
Yu, Jin; Zhu, Hong; Taheri, Saeid et al. (2018) Impact of nutrition on inflammation, tauopathy, and behavioral outcomes from chronic traumatic encephalopathy. J Neuroinflammation 15:277
Jenkins, Laura M; Horst, Ben; Lancaster, Carly L et al. (2018) Dually modified transmembrane proteoglycans in development and disease. Cytokine Growth Factor Rev 39:124-136
Alam, Amer; Küng, Raphael; Kowal, Julia et al. (2018) Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1. Proc Natl Acad Sci U S A 115:E1973-E1982

Showing the most recent 10 out of 49 publications